Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter 
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

News

Hepatitis C Cure Rate 93% With Elbasvir/Grazoprevir for Genotype 1 or 4

December 1, 2016

Sustained virologic response 12 weeks after elbasvir/grazoprevir (EBR/GZR, Zepatier) therapy ended (SVR12) reached 93% among HCV genotype 1 and 4 patients in the double-blind, placebo-controlled C-CORAL trial. SVR12 rates did not differ by sex, age or fibrosis stage.

HCV prevalence in the Asia/Pacific region and Russia ranges from 1% to 5%, with genotype 1b accounting for about half of infections. Fixed-dose one-tablet once-daily EBR/GZR is licensed for treatment of genotype 1 and 4 HCV in the United States, the European Union and elsewhere. C-CORAL collaborators conducted this trial to assess EBR/GZR efficacy and safety in Korea, Taiwan, Vietnam, Thailand, Australia and Russia. EBV is an NS5A inhibitor, and GZR is an NS3/4A protease inhibitor.

View Full Article


Related Stories

Liver Cancer Risk 60% Lower After SVR in Nationwide Danish Study
Spurred by Success of Remote Hepatitis C Care, Program Targets Remote Primary Care
Coverage of The Liver Meeting 2016 at TheBodyPRO.com


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Advertisement